CP-195543   Click here for help

GtoPdb Ligand ID: 6155

Synonyms: CP 195543 | CP-195,543 | CP195543
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: CP-195543 (CP-195,543) is a leukotriene B4 receptor antagonist for the treatment of inflammatory diseases. It is the follow-up compound to CP105696 whose development was discontinued due to unfavourable pharmacodynamic properties. Preclinical pharmacology for CP-195543 is reported by Showell et al. (1998) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 66.76
Molecular weight 428.12
XLogP 5.6
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES OC1C(COc2c1ccc(c2)c1cc(ccc1C(=O)O)C(F)(F)F)Cc1ccccc1
Isomeric SMILES O[C@@H]1[C@H](COc2c1ccc(c2)c1cc(ccc1C(=O)O)C(F)(F)F)Cc1ccccc1
InChI InChI=1S/C24H19F3O4/c25-24(26,27)17-7-9-18(23(29)30)20(12-17)15-6-8-19-21(11-15)31-13-16(22(19)28)10-14-4-2-1-3-5-14/h1-9,11-12,16,22,28H,10,13H2,(H,29,30)/t16-,22+/m0/s1
No information available.
Summary of Clinical Use Click here for help
Phase 2 clinical trial NCT00424294 which was designed to evaluate the efficacy, safety and tolerability of CP-195543 and celecoxib dual therapy in rheumatoid arthritis patients was terminated in 2007 following interim efficacy and safety analysis, which showed that CP-195543 exhibited a poor tolerability profile and high discontinuation rate.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00424294 A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis Phase 2 Interventional Pfizer